AU2016308818B2 - Clinical formulations - Google Patents

Clinical formulations Download PDF

Info

Publication number
AU2016308818B2
AU2016308818B2 AU2016308818A AU2016308818A AU2016308818B2 AU 2016308818 B2 AU2016308818 B2 AU 2016308818B2 AU 2016308818 A AU2016308818 A AU 2016308818A AU 2016308818 A AU2016308818 A AU 2016308818A AU 2016308818 B2 AU2016308818 B2 AU 2016308818B2
Authority
AU
Australia
Prior art keywords
cells
solution
cell
preparation
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016308818A
Other languages
English (en)
Other versions
AU2016308818A1 (en
Inventor
Roger GAY
Judson Ratliff
Romma E. Southwick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Institute for Regenerative Medicine
Original Assignee
Astellas Institute for Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Institute for Regenerative Medicine filed Critical Astellas Institute for Regenerative Medicine
Publication of AU2016308818A1 publication Critical patent/AU2016308818A1/en
Application granted granted Critical
Publication of AU2016308818B2 publication Critical patent/AU2016308818B2/en
Priority to AU2022206757A priority Critical patent/AU2022206757B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dentistry (AREA)
  • Reproductive Health (AREA)
AU2016308818A 2015-08-18 2016-08-18 Clinical formulations Active AU2016308818B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022206757A AU2022206757B2 (en) 2015-08-18 2022-07-20 Clinical formulations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562206821P 2015-08-18 2015-08-18
US62/206,821 2015-08-18
PCT/US2016/047545 WO2017031312A1 (en) 2015-08-18 2016-08-18 Clinical formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022206757A Division AU2022206757B2 (en) 2015-08-18 2022-07-20 Clinical formulations

Publications (2)

Publication Number Publication Date
AU2016308818A1 AU2016308818A1 (en) 2018-04-05
AU2016308818B2 true AU2016308818B2 (en) 2022-04-21

Family

ID=56843032

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016308818A Active AU2016308818B2 (en) 2015-08-18 2016-08-18 Clinical formulations
AU2022206757A Active AU2022206757B2 (en) 2015-08-18 2022-07-20 Clinical formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022206757A Active AU2022206757B2 (en) 2015-08-18 2022-07-20 Clinical formulations

Country Status (15)

Country Link
US (4) US11013808B2 (enExample)
EP (1) EP3334415A1 (enExample)
JP (3) JP7043392B2 (enExample)
KR (3) KR20230058544A (enExample)
CN (2) CN108697641A (enExample)
AU (2) AU2016308818B2 (enExample)
BR (1) BR112018003031B1 (enExample)
EA (2) EA037915B1 (enExample)
HK (1) HK1256839A1 (enExample)
IL (3) IL299326A (enExample)
MX (2) MX2018002038A (enExample)
PH (1) PH12018500371B1 (enExample)
SG (1) SG10201913250SA (enExample)
TW (2) TWI833293B (enExample)
WO (1) WO2017031312A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9993427B2 (en) * 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
MX2017008737A (es) 2014-12-30 2018-01-25 Cell Cure Neurosciences Ltd Poblaciones de celulas rpe y metodos para generar las mismas.
CA2980580C (en) 2015-03-23 2024-01-23 Astellas Institute For Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
WO2017031312A1 (en) 2015-08-18 2017-02-23 Astellas Institute For Regenerative Medicine Clinical formulations
JP7067744B2 (ja) * 2016-06-30 2022-05-16 株式会社ヘリオス 移植用媒体
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
KR20240161220A (ko) * 2017-12-29 2024-11-12 셀 큐어 뉴로사이언시스 리미티드 망막 색소 상피 세포 조성물
KR20220054359A (ko) 2019-08-28 2022-05-02 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 질병을 치료하는 방법
TW202122573A (zh) 2019-08-28 2021-06-16 安斯泰來再生醫藥協會 治療血管疾病之組成物及方法
IL292610A (en) 2019-10-30 2022-07-01 Astellas Inst For Regenerative Medicine Methods for the production of retinal pigment epithelial cells
JP7018527B1 (ja) 2020-12-16 2022-02-10 アニコム先進医療研究所株式会社 細胞の保存方法および細胞懸濁液
WO2023288115A1 (en) * 2021-07-15 2023-01-19 Sio2 Medical Products, Inc. Preservative composition for nucleic acids and biological samples and methods of use
JPWO2023176906A1 (enExample) * 2022-03-16 2023-09-21
CA3259999A1 (en) 2022-07-18 2024-01-25 Astellas Institute For Regenerative Medicine METHODS OF TREATING A BRAIN INJURY
JP2025530638A (ja) 2022-08-23 2025-09-17 アステラス インスティテュート フォー リジェネレイティブ メディシン 光受容体レスキュー細胞（ｐｒｃ）組成物および眼障害の処置のための方法
EP4659755A1 (en) * 2023-02-14 2025-12-10 RACTHERA Co., Ltd. Therapeutic drug for retinal pigment epithelium tears
WO2025122978A1 (en) * 2023-12-06 2025-06-12 Bluerock Therapeutics Lp Cell cryopreservation and delivery vehicle and methods of using the same
FR3158635A1 (fr) * 2024-01-26 2025-08-01 Treefrog Therapeutics Composition biocompatible particulière comprenant des éléments cellulaires hétérogènes utile pour l’administration de thérapies cellulaires
WO2025158058A1 (fr) * 2024-01-26 2025-07-31 Treefrog Therapeutics Composition biocompatible comprenant des elements cellulaires heterogenes
FR3158633A1 (fr) * 2024-01-26 2025-08-01 Treefrog Therapeutics Composition biocompatible comprenant des éléments cellulaires hétérogènes
WO2025204688A1 (ja) * 2024-03-26 2025-10-02 株式会社ダイセル リン脂質膜保護用液体組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0562188A1 (en) * 1992-03-27 1993-09-29 Chung-Ho Chen Composition for tissues to sustain viability and biological functions in surgery and storage
EP0781547A1 (en) * 1995-12-22 1997-07-02 Chemedica S.A. Sodium hyaluronate based ophthalmic formulation for use in eye surgery
WO2014095953A1 (en) * 2012-12-18 2014-06-26 Gambro Lundia Ab Dialysis composition

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654266A (en) * 1992-02-10 1997-08-05 Chen; Chung-Ho Composition for tissues to sustain viability and biological functions in surgery and storage
RU2142282C1 (ru) 1993-06-04 1999-12-10 Биотайм, Инк Раствор кровезаменителя на водной основе и способ его получения
CN1152668C (zh) * 1997-08-22 2004-06-09 清水制药株式会社 含有葡萄糖的制剂
GB2336109A (en) 1998-04-07 1999-10-13 Univ Bristol Ophthalmic Irrigating Solution
WO2001051065A1 (en) 2000-01-11 2001-07-19 Ophtecs Corporation Perfusion liquid preparations for ophthalmic operations
US7084157B2 (en) * 2002-05-17 2006-08-01 Rajeev Raut Ophthalmic pharmaceutical compositions and methods for treating ocular inflammation
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
EP2438814A3 (en) 2004-01-23 2012-10-03 Advanced Cell Technology, Inc. Improved modalities for the treatment of degenerative diseases of the retina
US20190282622A1 (en) 2004-01-23 2019-09-19 Astellas Institute For Regenerative Medicine Modalities for the treatment of degenerative diseases of the retina
EP2377925A1 (en) 2006-04-14 2011-10-19 Advanced Cell Technology, Inc. Hemangio-colony forming cells
EP2617428A1 (en) 2006-08-15 2013-07-24 Agency for Science, Technology and Research Mesenchymal stem cell conditioned medium
DK2209888T3 (da) 2007-10-12 2020-01-20 Astellas Inst For Regenerative Medicine Forbedrede fremgangsmåder til fremstilling af rpe-celler og sammensætninger af rpe-celler
KR20210003301A (ko) 2008-05-06 2021-01-11 아스텔라스 인스티튜트 포 리제너러티브 메디슨 다능성 줄기세포로부터 유도된 탈핵 적혈구계 세포를 생산하는 방법
CA3186451A1 (en) 2008-05-06 2009-11-12 Astellas Institute For Regenerative Medicine Hemangio colony forming cells and non-engrafting hemangio cells
KR20120102709A (ko) 2009-11-17 2012-09-18 어드밴스드 셀 테크놀로지, 인코포레이티드 인간 ｒｐｅ 세포의 생산 방법 및 인간 ｒｐｅ 세포의 제약 제제
WO2011069127A1 (en) 2009-12-04 2011-06-09 Stem Cell & Regenerative Medicine International, Inc. Large scale generation of functional megakaryocytes and platelets from human embryonic stem cells under stromal-free conditions
US8822218B2 (en) 2009-12-04 2014-09-02 Stem Cell & Regenerative Medicine International, Inc. Method of generating natural killer cells and dendritic cells from human embryonic stem cell-derived hemangioblasts
WO2012012803A2 (en) 2010-07-23 2012-01-26 Advanced Cell Technology, Inc. Methods for detection of rare subpopulations of cells and highly purified compositions of cells
TW202434266A (zh) 2011-11-14 2024-09-01 安斯泰來再生醫藥協會 人類rpe細胞之醫藥組合物及其用途
TW202537630A (zh) 2011-11-30 2025-10-01 美商安斯泰來再生醫藥協會 利用血管母細胞產生間葉基質細胞之方法
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
PL2788472T3 (pl) 2011-12-06 2019-06-28 Astellas Institute For Regenerative Medicine Sposób ukierunkowanego różnicowania z wytwarzaniem komórek śródbłonka rogówki
CN103783031B (zh) * 2012-10-29 2015-11-18 四川新生命干细胞科技股份有限公司 一种细胞保存液
CA3177929A1 (en) 2012-12-21 2014-06-26 Astellas Institute For Regenerative Medicine Methods for production of platelets from pluripotent stem cells and compositions thereof
EP4292600A3 (en) 2013-03-15 2024-04-10 Astellas Institute for Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20160175362A1 (en) 2014-03-14 2016-06-23 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
US20160175361A1 (en) 2014-03-14 2016-06-23 Advanced Cell Technology, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
EP3189135B1 (en) 2014-09-05 2021-06-02 Astellas Institute for Regenerative Medicine Retinal ganglion cells and progenitors thereof
CA2980580C (en) 2015-03-23 2024-01-23 Astellas Institute For Regenerative Medicine Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
WO2017031312A1 (en) * 2015-08-18 2017-02-23 Astellas Institute For Regenerative Medicine Clinical formulations
TW202122573A (zh) 2019-08-28 2021-06-16 安斯泰來再生醫藥協會 治療血管疾病之組成物及方法
KR20220054359A (ko) 2019-08-28 2022-05-02 아스텔라스 인스티튜트 포 리제너러티브 메디슨 혈관 질병을 치료하는 방법
IL292610A (en) 2019-10-30 2022-07-01 Astellas Inst For Regenerative Medicine Methods for the production of retinal pigment epithelial cells
MX2023013079A (es) 2021-05-03 2023-11-16 Astellas Inst For Regenerative Medicine Metodos de generacion de celulas maduras del endotelio corneal.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0562188A1 (en) * 1992-03-27 1993-09-29 Chung-Ho Chen Composition for tissues to sustain viability and biological functions in surgery and storage
EP0781547A1 (en) * 1995-12-22 1997-07-02 Chemedica S.A. Sodium hyaluronate based ophthalmic formulation for use in eye surgery
WO2014095953A1 (en) * 2012-12-18 2014-06-26 Gambro Lundia Ab Dialysis composition

Also Published As

Publication number Publication date
KR102411018B1 (ko) 2022-06-20
JP7449915B2 (ja) 2024-03-14
EA037915B1 (ru) 2021-06-07
US20240350639A1 (en) 2024-10-24
EP3334415A1 (en) 2018-06-20
JP2022040140A (ja) 2022-03-10
AU2022206757B2 (en) 2024-09-05
PH12018500371B1 (en) 2023-01-20
JP2018523682A (ja) 2018-08-23
NZ740608A (en) 2023-09-29
US11957754B2 (en) 2024-04-16
EA201890516A1 (ru) 2018-09-28
EA202190722A1 (ru) 2021-10-29
TWI833293B (zh) 2024-02-21
US20190030168A1 (en) 2019-01-31
MX2018002038A (es) 2018-07-06
US11013808B2 (en) 2021-05-25
BR112018003031B1 (pt) 2023-12-26
US12419958B2 (en) 2025-09-23
MX2022010363A (es) 2022-09-21
TW201717912A (zh) 2017-06-01
IL257551B (en) 2022-04-01
BR112018003031A2 (pt) 2018-09-18
CN108697641A (zh) 2018-10-23
IL291163A (en) 2022-05-01
IL291163B2 (en) 2023-05-01
KR20230058544A (ko) 2023-05-03
KR102651291B1 (ko) 2024-03-26
AU2022206757A1 (en) 2022-08-18
KR20180048722A (ko) 2018-05-10
WO2017031312A1 (en) 2017-02-23
HK1256839A1 (zh) 2019-10-04
JP7043392B2 (ja) 2022-03-29
US20210275673A1 (en) 2021-09-09
AU2016308818A1 (en) 2018-04-05
CA2995977A1 (en) 2017-02-23
KR20220090583A (ko) 2022-06-29
CN119112939A (zh) 2024-12-13
SG10201913250SA (en) 2020-03-30
TW202245816A (zh) 2022-12-01
IL299326A (en) 2023-02-01
JP2024074803A (ja) 2024-05-31
PH12018500371A1 (en) 2018-08-29
IL257551A (en) 2018-04-30
TW202417023A (zh) 2024-05-01
US20190358330A9 (en) 2019-11-28
TWI772270B (zh) 2022-08-01
IL291163B1 (en) 2023-01-01
US20260053930A1 (en) 2026-02-26

Similar Documents

Publication Publication Date Title
AU2022206757B2 (en) Clinical formulations
GB2496969A (en) Retinal pigment epithelial cells
US20260043008A1 (en) Cell cryopreservative formulations and methods of use
CA2995977C (en) Clinical formulations
TWI915731B (zh) 臨床調配物
NZ740608B2 (en) Clinical formulations
EA047097B1 (ru) Клинические композиции
JP2015514107A (ja) 角膜増殖のための組成物及び方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)